Evolving therapeutics in acid-related disorders of the gut: is vonoprazan the drug of the next decade
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20242442Keywords:
Erosive esophagitis, Gastroesophageal reflux disease, Proton pump inhibitors, Potassium-competitive acid blockers, VonoprazanAbstract
Vonoprazan a competitive potassium acid blocker (P-CAB) has been gaining traction compared to the use of traditional PPIs for the treatment of GERD and other acid-related disorders. We aim to review its comparative edge over the other widely used PPIs and its combination therapies in this article. It is also emerging to show superiority in mucosal and clinical healing rates in the already published literature. The mechanism of action of vonoprazan involves the antagonism of potassium channels present in parietal cells, thereby inhibiting gastric acid secretion. This distinctive mode of action effectively suppresses acid secretion in gastroesophageal reflux disease (GERD) and erosive esophagitis. For clinical usage, 20 mg of vonoprazan has been reported to be more effective in the management of acid-related disorders compared to conventional PPIs. This article underscores the need for continued research to fully elucidate the potential of vonoprazan in managing acid-related disorders, particularly in populations beyond Japan where its utility remains to be fully explored. It also aims to enlighten healthcare providers regarding its usage in the management of acid-related gastrointestinal disorders by providing insights into its clinical utility, practical considerations, & effective drug combinations eventually ameliorating patient outcomes and quality of life.
Metrics
References
Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther. 2005;108(3):294-307.
Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11:1756283.
Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: Pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55(4):409-18.
Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335(1):231-8.
Shin JM, Inatomi N, Munson K, Strugatsky D, Tokhtaeva E, Vagin O, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339(2):412-20.
Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011;81(9):1145-51.
Kinoshita Y, Sakurai Y, Takabayashi N, Kudou K, Araki T, Miyagi T, et al. Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study. Clin Transl Gastroenterol. 2019;10(11):101.
Kim MG, Im YJ, Lee JH, Kim EY, Yeom SW, Kim JS. Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study. Front Med. 2022;9:1076356.
Paperpile. 2024. Available at: https://paperpile.com/app/p/22cb7d50-4322-0b4e-b523-87170db81612.
Kubo K, Kimura N, Kato M. Potassium-competitive acid blocker-associated gastric mucosal lesions. Clin Endosc. 2024; Available at: http://dx.doi.org/10.5946/ce.2023.279. Accessed on 30th January 2024.
Gastric polyps’ regression after potassium‐competitive acid blocker cessation. 2022;23(5):358–9.
Haruma K, Kinoshita Y, Yao T, Kushima R, Akiyama J, Aoyama N, et al. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. BMC Gastroenterol. 2023;23(1):139.
Yoshizaki T, Morisawa T, Fujinami M, Matsuda T, Katayama N, Inoue K, et al. Propensity scores matching analysis: incidence and risk factors for “stardust” gastric mucosa, a novel gastric finding potentially induced by vonoprazan. Aliment Pharmacol Ther. 2021;53(1):94-102.
Miwa W, Hiratsuka T, Sato K, Fujino T, Kato Y. Development of white globe appearance lesions in the noncancerous stomach after vonoprazan administration: a report of two cases with a literature review. Clin J Gastroenterol. 2021;14(1):48-58.
Yousfi MM, el-Zimaity HM, al-Assi MT, Cole RA, Genta RM, Graham DY. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1995;9(2):209-12.
Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636-48.
Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, et al. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori. Digestion. 2020;101(6):743-51.
Zuberi BF, Ali FS, Rasheed T, Bader N, Hussain SM, Saleem A. Comparison of vonoprazan and amoxicillin dual therapy with standard triple therapy with proton pump inhibitor for helicobacter pylori eradication: a randomized control trial. Pak J Med Sci Q. 2022;38:965-9.
Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019-26.
Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials. Biomed Res Int. 2019;2019:9781212.
Peng X, Chen HW, Wan Y, Su PZ, Yu J, Liu JJ et al. Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study. Clin Exp Med. 2023;23(7):4011-9.
Mahrous N, Nasrelden E, Hassan M, Aboelmagd M. Efficacy of Vonoprazan-based triple therapy for cure of H. PyroliInfection among patients attending GIT outpatient clinic at Suez Canal University Hospital. Microbes and Infectious Diseases. 2023;4(2):506-13.
Katayama Y, Toyoda K, Kusano Y, Suda T, Adachi S, Terauchi I, et al. Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based first-line treatment failed. Gut. 2017;66(4):752-3.
Tanabe H, Ando K, Sato K, Ito T, Goto M, Sato T, et al. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. Dig Dis Sci. 2017;62(11):3069-76.
Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology. 2022;163(3):608-19.
Takeuchi T, Furuta T, Fujiwara Y, Sugimoto M, Kasugai K, Kusano M, et al. Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Aliment Pharmacol Ther. 2020;51(5):534-43.
Sue S, Ogushi M, Arima I, Kuwashima H, Nakao S, Naito M, et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. Helicobacter. 2018;23(2):12456.
Sugimoto M, Yamaoka Y. Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch Immunol Ther Exp. 2009;57(1):45-56.
Sue S, Shibata W, Sasaki T, Kaneko H, Irie K, Kondo M, et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol. 2019;34(4):686–92.
Suzuki H, Nishizawa T, Muraoka H, Hibi T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob Agents Chemother. 2009;53(4):1720-1.
Lu L, Wang Y, Ye J, Han Y, Lou G, Li Y, et al. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial. Helicobacter. 2023;28(1):12940.
Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870-8.
Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol. 2008;14(48):7361-70.
Chen S, Shen W, Liu Y, Dong Q, Shi Y. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial. Chin Med J. 2023;136(14):1690-8.
Mégraud F, Graham DY, Howden CW, Trevino E, Weissfeld A, Hunt B, et al. Rates of Antimicrobial Resistance in Helicobacter pylori Isolates from Clinical Trial Patients Across the US and Europe. Am J Gastroenterol. 2023;118(2):269-75.
Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5):1179-87.
Hershcovici T, Fass R. Nonerosive Reflux Disease (NERD) - An Update. J Neurogastroenterol Motil. 2010;16(1):8-21.
Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719-30.
Zhang M, Xiao Y, Chen M. The role of vonoprazan in patients with erosive esophagitis. Therap Adv Gastroenterol. 2022;15:17562848221122623.
Clayton SB, Rife CC, Singh ER, Kalbfleisch JH, Castell DO. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing. Dis Esophagus. 2012;25(8):682-6.
Simadibrata DM, Lesmana E, Fass R. A systematic review and meta‐analysis of the efficacy of vonoprazan for proton pump inhibitor‐resistant gastroesophageal reflux disease. Journal of Gastroenterology and Hepatology. 2024;39(5):796-805.
Kojima Y, Takeuchi T, Sanomura M, Higashino K, Kojima K, Fukumoto K, et al. Does the novel potassium-competitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A Multicenter Prospective Cross-Sectional Study. Digestion. 2018;97(1):70-5.
Ota K, Takeuchi T, Kojima Y, Kawaguchi S, Iwatsubo T, Hakoda A, et al. Administration of a standard dose of vonoprazan fumarate delays gastric emptying in Japanese healthy adults: a prospective clinical trial. J Gastroenterol. 2021;56(8):72-31.
Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci. 2010;55(9):2431-40.
Ratana-Amornpin S, Sanglutong L, Eiamsitrakoon T, Siramolpiwat S, Graham DY, Mahachai V. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. Helicobacter. 2023;28(6):13019.
Hu Y, Xu X, Ouyang YB, He C, Li NS, Xie C, et al. Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study. Helicobacter. 2022;27(4):12896.
Laine L, Sharma P, Mulford DJ, Hunt B, Leifke E, Smith N, et al. Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in us subjects. Am J Gastroenterol. 2022;117(7):1158-61.
Scarpignato C, Gatta L, Zullo A, Blandizzi C, SIF-AIGO-FIMMG Group, Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.
Higuchi K, Joh T, Nakada K, Haruma K. Is proton pump inhibitor therapy for reflux esophagitis sufficient?: a large real-world survey of Japanese patients. Intern Med. 2013;52(13):1447-54.
Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27-56.
Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69(2):224-30.
Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240-51.
Miyazaki H, Igarashi A, Takeuchi T, Teng L, Uda A, Deguchi H, et al. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review. J Gastroenterol Hepatol. 2019;34(8):1316-28.
Cheng Y, Liu J, Tan X, Dai Y, Xie C, Li X, et al. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021;66(1):19-28.
Tanabe H, Yoshino K, Ando K, Nomura Y, Ohta K, Satoh K, et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob. 2018;17(1):29.
Hamada K, Uedo N, Tonai Y, Arao M, Suzuki S, Iwatsubo T, et al. Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study. J Gastroenterol. 2019;54(2):122-30.
Hidaka Y, Imai T, Inaba T, Kagawa T, Omae K, Tanaka S. Efficacy of vonoprazan against bleeding from endoscopic submucosal dissection-induced gastric ulcers under antithrombotic medication: A cross-design synthesis of randomized and observational studies. PLoS One. 2021;16(12):261703.
Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, et al. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. Gastroenterology. 2023;164(1):61-71.